Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag + cyclosporine + androgen for transfusion-dependent non-severe aplastic anemia
ChiCTR2500114419Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hetrombopag in aplastic anemia, sponsored by West China Hospital of Sichuan University. Primary endpoint: Overall hematologic response rate at 24 weeks. Started Dec 2025; status: recruiting.
02
Drugs
hetrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2500114419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114419.